---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-314249"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:39:54.594724+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics prices upsized $350M public offering at $18.44/share

## Summary
- Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.
- Underwriters granted 30-day option for additional 2,847,071 shares.
- Net proceeds estimated at ~$328.5M ($377.9M if option exercised).
- Also borrowed $50M second tranche under Hercules Loan Agreement.
- Cash runway extended into Q1 2028 with combined resources.

## SEC filing metadata
- accession: 0001193125-25-314249
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312525314249/0001193125-25-314249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312525314249/d76666d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-314249
- JSON: https://secwatch.observer/filing/0001193125-25-314249.json
- Plain text: https://secwatch.observer/filing/0001193125-25-314249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.